GlassScriptPhysician profile
Sari Winans
NPI 1649677402
$16,033.90
in general payments reported to CMS, 2019-2025
40 companies · $4,283 in 2025
The $4,283 reported for 2025 was more than what 99% of Obstetrics & Gynecology (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Obstetrics & Gynecology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,581 · 2022: $3,101 · 2023: $2,864 · 2024: $4,205 · 2025: $4,283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,351.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,658.37 | 2021-2025 | |
| Gilead Sciences, INC. | $895.11 | 2021-2025 | Epclusa |
| Madrigal Pharmaceuticals | $774.86 | 2024-2025 | Rezdiffra |
| Ardelyx, INC. | $706.04 | 2022-2025 | Ibsrela |
| Novo Nordisk INC | $637.19 | 2022-2025 | Wegovy, Ozempic |
| Janssen Biotech, INC. | $635.90 | 2021-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $587.48 | 2021-2025 | Entyvio |
| Lilly USA, LLC | $555.11 | 2022-2025 | Omvoh, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $483.42 | 2021-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $476.75 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $403.73 | 2024-2025 | Zenpep, Vowst |
| Regeneron Healthcare Solutions, INC. | $382.03 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $379.32 | 2022-2025 | Sucraid, Sucraid |
| Astrazeneca Pharmaceuticals LP | $374.80 | 2022-2025 | Breztri, Airsupra |
| E.R. Squibb & Sons, L.L.C. | $312.09 | 2022-2024 | Eliquis, Zeposia |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sari Winans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.